VRDN
|Viridian Therapeutics Inc
NASDAQ
USD 17.41
-0.11|-0.63%
Current Price
USD 17.41
Change
USD -0.11 (-0.63%)
P/E Ratio
Dividend Yield
Market Cap
1.12B
Volume
662,619
Open
USD 17.32
Previous Close
USD 17.52
52-Week High
USD 27.20
52-Week Low
USD 9.90
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the...
Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Stephen F. Mahoney J.D., MBA
Employees:143
Headquarters:Waltham, USA
Website:www.viridiantherapeutics.com
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions